

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on July 7, 2008.

Frank C. Eisenschenk
Frank C. Eisenschenk, Ph.D., Patent Attorney

AMENDMENT UNDER 37 CFR
§1.825(a) THROUGH (c)
Patent Application
Docket No. ARS-123
Serial No. 10/573,726

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1614
Applicants : Amanda Proudfoot, Jeffrey Shaw
Serial No. : 10/573,726
Filed : March 28, 2007
Conf. No. : 2240
For : Novel CXCL8 Antagonists

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

AMENDMENT UNDER 37 CFR §1.825(a) THROUGH (c)

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures received in the above-identified patent application, please amend the subject application as follows, in order to comply with the requirements of 37 CFR §§1.821-1.825: